• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature
【24h】

Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature

机译：社区获得的肺炎中的皮质类固醇：对当前文献的综述

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To review the evidence and recommendations for the use of adjunctive corticosteroid therapy in community-acquired pneumonia (CAP). Data Sources: A literature search was conducted using PubMed (1993 to November 2020) using the search terms corticosteroids AND community-acquired pneumonia . Study Selection and Data Extraction: Pertinent randomized controlled trials, systematic reviews, and meta-analyses assessing the efficacy and safety of adjunctive corticosteroids in patients with pneumonia were evaluated for inclusion. Data Synthesis: Studies suggest that corticosteroids reduce time to clinical stability and length of hospital stay, but data regarding other important clinical outcomes, such as mortality, are limited. The greatest margin of benefit appears to be in patients with severe CAP. Evidence consistently demonstrates hyperglycemia as the most common adverse effect of corticosteroid therapy in CAP. Safety concerns regarding the potential impact of corticosteroids on the rate of CAP-related rehospitalizations require further investigation. Relevance to Patient Care and Clinical Practice: This review summarizes literature evaluating the efficacy and safety of adjunctive corticosteroids in patients with CAP. It also includes a discussion on current guideline recommendations, patient selection, corticosteroid regimens, adverse effect considerations, limitations, and future directions in this area of research. Conclusions: Studies reviewed suggest that corticosteroids are relatively beneficial and safe in patients with CAP, with the greatest benefit in severe CAP. Currently, the routine use of corticosteroids is not recommended by clinical practice guidelines with the exception of CAP and refractory septic shock. Further research is needed to better define the ideal role of corticosteroids in CAP.
机译：目的：回顾在社区获得性肺炎（CAP）中使用辅助皮质类固醇治疗的证据和建议。数据来源：使用PubMed（1993年至2020年11月）进行文献检索，检索词为皮质类固醇和社区获得性肺炎。研究选择和数据提取：评估肺炎患者使用辅助皮质类固醇的疗效和安全性的相关随机对照试验、系统评价和荟萃分析。数据综合：研究表明，皮质类固醇可缩短临床稳定时间和住院时间，但有关其他重要临床结果（如死亡率）的数据有限。获益最大的似乎是重度CAP患者。证据一致表明，高血糖是CAP患者皮质类固醇治疗最常见的不良反应。关于皮质类固醇对CAP相关再住院率的潜在影响的安全问题需要进一步调查。与患者护理和临床实践的相关性：这篇综述总结了评估辅助皮质类固醇在CAP患者中的疗效和安全性的文献。它还包括对当前指南建议、患者选择、皮质类固醇方案、不良反应考虑、局限性和该研究领域未来方向的讨论。结论：回顾性研究表明，皮质类固醇在CAP患者中相对有益且安全，在重度CAP患者中获益最大。目前，临床实践指南不建议常规使用皮质类固醇，但CAP和难治性败血性休克除外。需要进一步的研究来更好地定义皮质类固醇在CAP中的理想作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号